Wednesday, February 5, 2025
2/5/2025
Abstract Colorectal cancer (CRC) is both the third most common and deadliest cancer in the United States. Despite recent advances in treatment, the 5-year survival rate remains poor due to multiple factors including delayed diagnosis, chemoresistance, and disease heterogeneity. Altered expression of enteroendocrine protein signaling components consisting of Fibroblast Growth Factor Receptor 4 (FGFR4), its ligand Fibroblast Growth Factor 19 (FGF19), and co-receptor Klotho Beta (KLB) recently have been implicated in various cancers. Specific to CRC, the role of KLB remains elusive, although FGF19 and FGFR4 have more established oncogenic functions. An objective of this proposed research is to delineate KLB’s function in CRC. The work is predicated on the analysis of CRC RNA-seq data from The Cancer Genome Atlas (TCGA) database consistently showing significant repression in CRC generally and across all subtypes. Collectively, it is necessary to further investigate and validate KLB’s role in CRC, focusing on how KLB modulates oncogenic FGFR4-FGF19 signaling in the larger context of epithelial-mesenchymal transition (EMT) and tumorigenesis. Thus, our overall hypothesis is that KLB demonstrates tumor suppressor properties in CRC by negatively regulating oncogenic, EMT-promoting FGFR4-FGF19 signaling. Specific Aim 1 will test the hypothesis by analyzing detailed clinical parameters via informatics to assess the prognostic value of KLB deficiency in CRC and reveal its impact on tumor dynamics in vitro and in vivo. Our preliminary data reveals tumor-suppressor-like properties of KLB as its expression is directly associated with treatment success, microsatellite stability, survivability and inversely with pathologic stage. Additionally, KLB downregulation occurs as early as the adenoma stage further supported by a CRC cell line panel showing global KLB repression which directly correlated with differentiation status. Finally, KLB expression was enhanced in two separate in vitro CRC models of differentiation and its transgenic overexpression was associated with increased cellular organization and polarization of HT29 cells compared to CrisprCas9-induced knock down. Specific Aim 2 will investigate KLB’s mechanism of action by testing FGFR4-FGF19 signaling as the major effector pathway through which KLB affects CRC. In support of this Aim, we present compelling new preliminary evidence showing that KLB expression positively correlates with Farnesoid-X-Receptor (FXR), a known tumor suppressor and target of FGFR4 signaling, within the clinical data thereby indicating possible crosstalk. Additionally, chemical agonism of FXR induces KLB expression in Caco2 cells in vitro. By performing these studies, we expect to (i) Establish KLB’s clinical implications in CRC, and (ii) Demonstrate that KLB affects CRC mechanistically through regulation of FGFR4-FGF19 signaling. Overall, this study will establish a tentative role for KLB in CRC and how its presence impacts oncogenic FGFR4-FGF19 signaling. The ultimate goal of this proposal is to utilize KLB expression to predict prognosis, treatment response and serve as a potential therapeutic target for improving CRC patient outcomes.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).